Narayan Rajan1, Kristina S Boye2, Meaghan Gibbs3, Yoon Ji Lee4, Peter Davey5, Mark Ball5, Steve M Babineaux2. 1. Eli Lilly, Indianapolis, IN, USA. Electronic address: rajan_narayan@lilly.com. 2. Eli Lilly, Indianapolis, IN, USA. 3. Information Fulfillment Ltd., Hong Kong, China. 4. Eli Lilly Korea, Seoul, Korea. 5. PRIMA Consulting Group, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: To elicit utilities associated with type 2 diabetes medication-related attributes from South Korean and Taiwanese populations and to identify key drivers of preferences. METHODS: Data from 59 respondents from the general population in South Korea and Taiwan were analyzed. Respondents' preferences were elicited using a paper-based standard gamble questionnaire. Health states were designed to identify the utility or disutility of type 2 diabetes medication-related attributes, including dose frequency, nausea/vomiting (hereafter referred to as nausea), and weight change. RESULTS: The mean utility for the basic health state (encompassing current body weight and no nausea) was 0.754 ± 0.155 with weekly dose administration. Respondents showed a preference for weekly over daily administration (average increase in utility of 0.043 across all health states with weekly, vs. daily, administration). Nausea was associated with a decrease in utility (average decrease of -0.034 across all health states with, vs. without, nausea). Weight gain had little effect on utility (average decrease of 0.000 and 0.001 across all health states with, vs. without, 3% and 5% gain, respectively), although weight loss was associated with a small increase in utility (average increase of 0.028 and 0.029 across all health states with, vs. without, 3% and 5% loss, respectively). CONCLUSIONS: Utilities associated with type 2 diabetes medication-related attributes were elicited from a general population sample from South Korea and Taiwan. Treatment-related attributes, in particular dose frequency and nausea, had a measurable effect on utility and should be considered when selecting treatment regimens for South Korean or Taiwanese patients with type 2 diabetes. Copyright Â
OBJECTIVES: To elicit utilities associated with type 2 diabetes medication-related attributes from South Korean and Taiwanese populations and to identify key drivers of preferences. METHODS: Data from 59 respondents from the general population in South Korea and Taiwan were analyzed. Respondents' preferences were elicited using a paper-based standard gamble questionnaire. Health states were designed to identify the utility or disutility of type 2 diabetes medication-related attributes, including dose frequency, nausea/vomiting (hereafter referred to as nausea), and weight change. RESULTS: The mean utility for the basic health state (encompassing current body weight and no nausea) was 0.754 ± 0.155 with weekly dose administration. Respondents showed a preference for weekly over daily administration (average increase in utility of 0.043 across all health states with weekly, vs. daily, administration). Nausea was associated with a decrease in utility (average decrease of -0.034 across all health states with, vs. without, nausea). Weight gain had little effect on utility (average decrease of 0.000 and 0.001 across all health states with, vs. without, 3% and 5% gain, respectively), although weight loss was associated with a small increase in utility (average increase of 0.028 and 0.029 across all health states with, vs. without, 3% and 5% loss, respectively). CONCLUSIONS: Utilities associated with type 2 diabetes medication-related attributes were elicited from a general population sample from South Korea and Taiwan. Treatment-related attributes, in particular dose frequency and nausea, had a measurable effect on utility and should be considered when selecting treatment regimens for South Korean or Taiwanese patients with type 2 diabetes. Copyright Â